Johannes Herkel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Johannes Herkel has a total of 594 co-authors. Here are the top co-authors by number of shared publications:
Ansgar W. Lohse
Department of Medicine I, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Hamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
38 shared publications- Christoph Schramm
Department of Medicine I and Martin Zeitz Center for Rare Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
29 shared publications Antonella Carambia
22 shared publicationsAw Lohse
University Medical Centre Hamburg-Eppendorf, Department of Medicine I, Hamburg, Germany
21 shared publicationsC Schramm
Universitätsklinikum Hamburg-Eppendorf, 1. Medizinische Klinik, Hamburg
18 shared publicationsA. W. Lohse
14 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (12)
MiR-122 regulates liver tolerance
- 29 August 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (12)
Open AccessMiR-122 regulates liver tolerance
- Open Access
- 5 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1834595
Antigen-specific tolerance and control of autoimmunity effected by liver sinusoidal endothelial cells is unimpaired in liver fibrosis
Background and aims: Liver sinusoidal endothelial cells (LSECs) have a key role in maintaining organismal homeostasis by scavenging blood-borne molecules and inducing specific immune tolerance to ingested antigens. The scavenger and tolerance function of LSECs can be harnessed for specific treatment of autoimmune diseases by nanoparticle-mediated autoantigen delivery to LSECs. In liver fibrosis, which is a frequent condition in human populations, LSECs undergo changes promoting pro-fibrotic and pro-inflammatory activation of other hepatic cells, but it is unclear whether the scavenger and immune tolerance functions of LSECs are affected. Methods: Utilizing two mouse models of liver fibrosis, we explored the ability of LSECs to take up nanoparticles conjugated with antigen peptides, to present the ingested antigen peptides to T cells and to induce peptide-specific immune tolerance in vitro and in vivo in the context of autoimmune diseases. Results: LSECs from fibrotic livers showed few distinct adaptations regarding immune functions; however, overall LSEC identity was largely maintained. Accordingly, endocytosis of nanoparticles by LSECs in vivo , as well as processing and presentation of nanoparticle-bound antigen peptides was not compromised by liver fibrosis. LSECs from fibrotic livers maintained the ability to effectively induce the generation of regulatory T cells from conventional CD4 T cells. Hence, targeted delivery of autoantigen peptides to LSECs in vivo effectively induced specific tolerance despite liver fibrosis, providing protection in two models of experimental autoimmune disease. Analysis of datasets from human subjects with or without liver cirrhosis confirmed that scavenger and tolerance pathways in LSECs were preserved in human liver fibrosis. Conclusions: Scavenger activity and antigen-specific tolerance induction by LSECs are preserved in liver fibrosis. Thus, LSECs remain reliable mediators of homeostasis and tolerance under fibrotic conditions, and particularly suitable targets for nanomedicine products.
- 5 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1834595
Open AccessAntigen-specific tolerance and control of autoimmunity effected by liver sinusoidal endothelial cells is unimpaired in liver fibrosis
Background and aims: Liver sinusoidal endothelial cells (LSECs) have a key role in maintaining organismal homeostasis by scavenging blood-borne molecules and inducing specific immune tolerance to ingested antigens. The scavenger and tolerance function of LSECs can be harnessed for specific treatment of autoimmune diseases by nanoparticle-mediated autoantigen delivery to LSECs. In liver fibrosis, which is a frequent condition in human populations, LSECs undergo changes promoting pro-fibrotic and pro-inflammatory activation of other hepatic cells, but it is unclear whether the scavenger and immune tolerance functions of LSECs are affected. Methods: Utilizing two mouse models of liver fibrosis, we explored the ability of LSECs to take up nanoparticles conjugated with antigen peptides, to present the ingested antigen peptides to T cells and to induce peptide-specific immune tolerance in vitro and in vivo in the context of autoimmune diseases. Results: LSECs from fibrotic livers showed few distinct adaptations regarding immune functions; however, overall LSEC identity was largely maintained. Accordingly, endocytosis of nanoparticles by LSECs in vivo , as well as processing and presentation of nanoparticle-bound antigen peptides was not compromised by liver fibrosis. LSECs from fibrotic livers maintained the ability to effectively induce the generation of regulatory T cells from conventional CD4 T cells. Hence, targeted delivery of autoantigen peptides to LSECs in vivo effectively induced specific tolerance despite liver fibrosis, providing protection in two models of experimental autoimmune disease. Analysis of datasets from human subjects with or without liver cirrhosis confirmed that scavenger and tolerance pathways in LSECs were preserved in human liver fibrosis. Conclusions: Scavenger activity and antigen-specific tolerance induction by LSECs are preserved in liver fibrosis. Thus, LSECs remain reliable mediators of homeostasis and tolerance under fibrotic conditions, and particularly suitable targets for nanomedicine products.
- Top Cited PapersOpen Access
- 19 March 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (1) , 71-90
Integrative omics and phase IIa clinical trial identify TNF as key node in autoimmune hepatitis
- 19 March 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (1) , 71-90
Top Cited PapersOpen AccessIntegrative omics and phase IIa clinical trial identify TNF as key node in autoimmune hepatitis
- Open Access
- 19 September 2023
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 17 (1) , 79-91
IFNγ and CTLA-4 Drive Hepatic CD4 T-Cell Tolerance and Protection From Autoimmunity in Mice
- 19 September 2023
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 17 (1) , 79-91
Open AccessIFNγ and CTLA-4 Drive Hepatic CD4 T-Cell Tolerance and Protection From Autoimmunity in Mice
- Open Access
- 27 May 2023
- Published by Wiley in Immunology
- Vol. 170 (2) , 214-229
Autoantigen‐selected B cells are bystanders in spontaneous T cell‐driven experimental autoimmune hepatitis
Autoreactive B cells are considered pathogenic drivers in many autoimmune diseases; however, it is not clear whether autoimmune B cells are invariably pathogenic or whether they can also arise as bystanders of T cell‐driven autoimmune pathology. Here, we studied the B cell response in an autoantigen‐ and CD4+ T cell‐driven model of autoimmune hepatitis (AIH), the Alb‐iGP_Smarta mouse in which expression of a viral model antigen (GP) in hepatocytes and its recognition by GP‐specific CD4+ T cells causes spontaneous AIH‐like disease. T cell‐driven AIH in Alb‐iGP_Smarta mice was marked by autoantibodies and hepatic infiltration of plasma cells and B cells, particularly of isotype‐switched memory B cells, indicating antigen‐driven selection and activation. Immunosequencing of B cell receptor repertoires confirmed B cell expansion selectively in the liver, which was most likely driven by the hepatic GP model antigen, as indicated by branched networks of connected sequences and elevated levels of IgG antibodies to GP. However, intrahepatic B cells did not produce increased levels of cytokines and their depletion with anti‐CD20 antibody did not alter the CD4+ T cell response in Alb‐iGP_Smarta mice. Moreover, B cell depletion did not prevent spontaneous liver inflammation and AIH‐like disease in Alb‐iGP_Smarta mice. In conclusion, selection and isotype‐switch of liver‐infiltrating B cells was dependent on the presence of CD4+ T cells recognizing liver antigen. However, recognition of hepatic antigen by CD4+ T cells and CD4+ T cell‐mediated hepatitis was not dependent on B cells. Thus, autoreactive B cells can be bystanders and need not be drivers of liver inflammation in AIH.
- 27 May 2023
- Published by Wiley in Immunology
- Vol. 170 (2) , 214-229
Open AccessAutoantigen‐selected B cells are bystanders in spontaneous T cell‐driven experimental autoimmune hepatitis
Autoreactive B cells are considered pathogenic drivers in many autoimmune diseases; however, it is not clear whether autoimmune B cells are invariably pathogenic or whether they can also arise as bystanders of T cell‐driven autoimmune pathology. Here, we studied the B cell response in an autoantigen‐ and CD4+ T cell‐driven model of autoimmune hepatitis (AIH), the Alb‐iGP_Smarta mouse in which expression of a viral model antigen (GP) in hepatocytes and its recognition by GP‐specific CD4+ T cells causes spontaneous AIH‐like disease. T cell‐driven AIH in Alb‐iGP_Smarta mice was marked by autoantibodies and hepatic infiltration of plasma cells and B cells, particularly of isotype‐switched memory B cells, indicating antigen‐driven selection and activation. Immunosequencing of B cell receptor repertoires confirmed B cell expansion selectively in the liver, which was most likely driven by the hepatic GP model antigen, as indicated by branched networks of connected sequences and elevated levels of IgG antibodies to GP. However, intrahepatic B cells did not produce increased levels of cytokines and their depletion with anti‐CD20 antibody did not alter the CD4+ T cell response in Alb‐iGP_Smarta mice. Moreover, B cell depletion did not prevent spontaneous liver inflammation and AIH‐like disease in Alb‐iGP_Smarta mice. In conclusion, selection and isotype‐switch of liver‐infiltrating B cells was dependent on the presence of CD4+ T cells recognizing liver antigen. However, recognition of hepatic antigen by CD4+ T cells and CD4+ T cell‐mediated hepatitis was not dependent on B cells. Thus, autoreactive B cells can be bystanders and need not be drivers of liver inflammation in AIH.
- Open Access
- 5 July 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (6) , 1532-1544
Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis
- 5 July 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (6) , 1532-1544
Open AccessInflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis
- Open Access
- 5 May 2022
- Published by Springer Nature in Seminars in Immunopathology
- Vol. 44 (4) , 475-484
Harnessing the liver to induce antigen-specific immune tolerance
Autoimmune diseases develop when the adaptive immune system attacks the body’s own antigens leading to tissue damage. At least 80 different conditions are believed to have an autoimmune aetiology, including rheumatoid arthritis, type I diabetes, multiple sclerosis or systemic lupus erythematosus. Collectively, autoimmune diseases are a leading cause of severe health impairment along with substantial socioeconomic costs. Current treatments are mostly symptomatic and non-specific, and it is typically not possible to cure these diseases. Thus, the development of more causative treatments that suppress only the pathogenic immune responses, but spare general immunity is of great biomedical interest. The liver offers considerable potential for development of such antigen-specific immunotherapies, as it has a distinct physiological capacity to induce immune tolerance. Indeed, the liver has been shown to specifically suppress autoimmune responses to organ allografts co-transplanted with the liver or to autoantigens that were transferred to the liver. Liver tolerance is established by a unique microenvironment that facilitates interactions between liver-resident antigen-presenting cells and lymphocytes passing by in the low blood flow within the hepatic sinusoids. Here, we summarise current concepts and mechanisms of liver immune tolerance, and review present approaches to harness liver tolerance for antigen-specific immunotherapy.
- 5 May 2022
- Published by Springer Nature in Seminars in Immunopathology
- Vol. 44 (4) , 475-484
Open AccessHarnessing the liver to induce antigen-specific immune tolerance
Autoimmune diseases develop when the adaptive immune system attacks the body’s own antigens leading to tissue damage. At least 80 different conditions are believed to have an autoimmune aetiology, including rheumatoid arthritis, type I diabetes, multiple sclerosis or systemic lupus erythematosus. Collectively, autoimmune diseases are a leading cause of severe health impairment along with substantial socioeconomic costs. Current treatments are mostly symptomatic and non-specific, and it is typically not possible to cure these diseases. Thus, the development of more causative treatments that suppress only the pathogenic immune responses, but spare general immunity is of great biomedical interest. The liver offers considerable potential for development of such antigen-specific immunotherapies, as it has a distinct physiological capacity to induce immune tolerance. Indeed, the liver has been shown to specifically suppress autoimmune responses to organ allografts co-transplanted with the liver or to autoantigens that were transferred to the liver. Liver tolerance is established by a unique microenvironment that facilitates interactions between liver-resident antigen-presenting cells and lymphocytes passing by in the low blood flow within the hepatic sinusoids. Here, we summarise current concepts and mechanisms of liver immune tolerance, and review present approaches to harness liver tolerance for antigen-specific immunotherapy.
- Open Access
- 16 September 2021
- Published by Springer Nature in Seminars in Immunopathology
- Vol. 43 (4) , 477-479
Mediators of liver inflammation and carcinogenesis
- 16 September 2021
- Published by Springer Nature in Seminars in Immunopathology
- Vol. 43 (4) , 477-479
Open AccessMediators of liver inflammation and carcinogenesis
- Open Access
- 22 March 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (6)
Failure of thymic deletion and instability of autoreactive Tregs drive autoimmunity in immune-privileged liver
The liver is an immune-privileged organ that can deactivate autoreactive T cells. Yet in autoimmune hepatitis (AIH), autoreactive T cells can defy hepatic control and attack the liver. To elucidate how tolerance to self-antigens is lost during AIH pathogenesis, we generated a spontaneous mouse model of AIH, based on recognition of an MHC class II–restricted model peptide in hepatocytes by autoreactive CD4 + T cells. We found that the hepatic peptide was not expressed in the thymus, leading to deficient thymic deletion and resulting in peripheral abundance of autoreactive CD4 + T cells. In the liver, autoreactive CD4 + effector T cells accumulated within portal ectopic lymphoid structures and maturated toward pathogenic IFN-γ and TNF coproducing cells. Expansion and pathogenic maturation of autoreactive effector T cells was enabled by a selective increase of plasticity and instability of autoantigen-specific Tregs but not of nonspecific Tregs. Indeed, antigen-specific Tregs were reduced in frequency and manifested increased IL-17 production, reduced epigenetic demethylation, and reduced expression of Foxp3 . As a consequence, autoantigen-specific Tregs had a reduced suppressive capacity, as compared with that of nonspecific Tregs. In conclusion, loss of tolerance and the pathogenesis of AIH were enabled by combined failure of thymic deletion and peripheral regulation.
- 22 March 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (6)
Open AccessFailure of thymic deletion and instability of autoreactive Tregs drive autoimmunity in immune-privileged liver
The liver is an immune-privileged organ that can deactivate autoreactive T cells. Yet in autoimmune hepatitis (AIH), autoreactive T cells can defy hepatic control and attack the liver. To elucidate how tolerance to self-antigens is lost during AIH pathogenesis, we generated a spontaneous mouse model of AIH, based on recognition of an MHC class II–restricted model peptide in hepatocytes by autoreactive CD4 + T cells. We found that the hepatic peptide was not expressed in the thymus, leading to deficient thymic deletion and resulting in peripheral abundance of autoreactive CD4 + T cells. In the liver, autoreactive CD4 + effector T cells accumulated within portal ectopic lymphoid structures and maturated toward pathogenic IFN-γ and TNF coproducing cells. Expansion and pathogenic maturation of autoreactive effector T cells was enabled by a selective increase of plasticity and instability of autoantigen-specific Tregs but not of nonspecific Tregs. Indeed, antigen-specific Tregs were reduced in frequency and manifested increased IL-17 production, reduced epigenetic demethylation, and reduced expression of Foxp3 . As a consequence, autoantigen-specific Tregs had a reduced suppressive capacity, as compared with that of nonspecific Tregs. In conclusion, loss of tolerance and the pathogenesis of AIH were enabled by combined failure of thymic deletion and peripheral regulation.